--- title: "ABVC BioPharma, Inc. (ABVC.US)" type: "Symbol" locale: "en" url: "https://longbridge.com/en/quote/ABVC.US.md" symbol: "ABVC.US" name: "ABVC BioPharma, Inc." industry: "Biotechnology" datetime: "2026-05-21T21:38:20.509Z" locales: - [en](https://longbridge.com/en/quote/ABVC.US.md) - [zh-CN](https://longbridge.com/zh-CN/quote/ABVC.US.md) - [zh-HK](https://longbridge.com/zh-HK/quote/ABVC.US.md) --- # ABVC BioPharma, Inc. (ABVC.US) ## Company Overview ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus, which is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer; ABV-2001, an intraocular irrigation solution; ABV-2002, a corneal Storage Solution; and ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer. The company has a co-development agreement with Rgene Corporation and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. | Item | Detail | |------|--------| | Industry | Biotechnology | | Exchange | US Market | | Website | [www.abvcpharma.com](https://www.abvcpharma.com) | ## Key Drivers > *AI-analyzed key factors driving this stock's performance* ## Longbridge Financial Score™: C > *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge* > Updated: 2026-05-21T04:30:18.000Z **Overall: C (0.49)** **Industry**: Biotechnology | Metric | Value | |--------|-------| | Industry Ranking | 0 / 385 | | Industry Median | C | | Industry Average | C | - **Style**: Value - Stocks where the company's main business is in a mature stage. - **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns. **Multi Score**: C #### Style Score Score: | Indicator | Value | Rating | |-----------|-------|--------| | Revenue YoY | 0.00% | | | Net Profit YoY | -196.37% | | | P/B Ratio | 2.48 | | | Dividend Ratio | 0.00% | | #### Size Score Score: | Indicator | Value | Rating | |-----------|-------|--------| | Market Cap | 26731197.90 | | | Revenue | 0.00 | | #### Multi Score Score: C | Indicator | Value | Rating | |-----------|-------|--------| | ROE | -49.74% | E | | Profit Margin | -636.31% | E | | Gross Margin | 100.00% | A | | Revenue YoY | 56.52% | A | | Net Profit YoY | -11.47% | D | | Total Assets YoY | 46.42% | A | | Net Assets YoY | 81.63% | A | | Cash Flow Margin | -15.72% | D | | OCF YoY | 56.52% | A | | Turnover | 0.04 | E | | Gearing Ratio | 31.56% | B | ```chart-data:radar { "title": "Longbridge Financial Score - ABVC BioPharma, Inc.", "chart_type": "radar", "dimensions": [ { "name": "Style Score", "grade": "", "indicators": [ { "name": "Revenue YoY", "value": "0.00%", "rating": "" }, { "name": "Net Profit YoY", "value": "-196.37%", "rating": "" }, { "name": "P/B Ratio", "value": "2.48", "rating": "" }, { "name": "Dividend Ratio", "value": "0.00%", "rating": "" } ] }, { "name": "Size Score", "grade": "", "indicators": [ { "name": "Market Cap", "value": "26731197.90", "rating": "" }, { "name": "Revenue", "value": "0.00", "rating": "" } ] }, { "name": "Multi Score", "grade": "C", "indicators": [ { "name": "ROE", "value": "-49.74%", "rating": "E" }, { "name": "Profit Margin", "value": "-636.31%", "rating": "E" }, { "name": "Gross Margin", "value": "100.00%", "rating": "A" }, { "name": "Revenue YoY", "value": "56.52%", "rating": "A" }, { "name": "Net Profit YoY", "value": "-11.47%", "rating": "D" }, { "name": "Total Assets YoY", "value": "46.42%", "rating": "A" }, { "name": "Net Assets YoY", "value": "81.63%", "rating": "A" }, { "name": "Cash Flow Margin", "value": "-15.72%", "rating": "D" }, { "name": "OCF YoY", "value": "56.52%", "rating": "A" }, { "name": "Turnover", "value": "0.04", "rating": "E" }, { "name": "Gearing Ratio", "value": "31.56%", "rating": "B" } ] } ] } ``` ## Valuation Analysis | Metric | Current | Industry Ranking | High | Median | Low | |--------|---------|-----------------|------|--------|-----| | PE (TTM) | -3.10 | 299/385 | - | - | - | | PB | 2.48 | 218/385 | 9.32 | 4.75 | 3.02 | | PS (TTM) | 43.25 | - | 158.59 | 65.87 | 43.25 | | Dividend Yield | 0.00% | - | - | - | - | ## Peer Comparison | Rank | Name | Profit | Growth | Operation | Security | Cash | Rating | | --- | --- | --- | --- | --- | --- | --- | --- | | 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A | | 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A | | 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A | | 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A | | 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A | ## Institutional View ### Analyst Rating Distribution > As of 2023-05-24T04:00:00.000Z Total Analysts: **1** | Rating | Count | Percentage | |--------|-------|-----------| ### Target Price Forecast | Metric | Price | |--------|-------| | Current Price | 1.11 | | Highest Target | undefined | | Lowest Target | undefined | ## References - [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/ABVC.US/overview.md) - [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/ABVC.US/norm.md) - [Related News](https://longbridge.com/en/quote/ABVC.US/news.md) - [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/ABVC.US/filings.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**